$IPX

IperionX Limited's average price target dropped from $45.17 to $41.45, with a range of $26 to $55, according to 5 analysts. This implies a 146% upside from the Sep. 30 closing price. The consensus rating remains 'Buy' across 6 analysts.

Iperionx Ltd. [IPX] began commercial titanium production, expanded capacity, and secured U.S. government contracts. The company reported a net loss of $66.8M, attributing it to ramp-up costs, but highlighted strong funding and project economics for future growth.

IperionX received a $11.5M task order from the US Army, part of a $99M contract, to expand titanium production capacity. The funding targets equipment for continuous manufacturing and in-house finishing. Additional $6.9M in options could increase the total to $25.4M, subject to government approval. The project aims to reduce reliance on foreign feedstocks and improve domestic titanium production.

IperionX (ASX: IPX) validated its GenX titanium production platform, processing 500kg of powder with improved efficiency. GenX achieved six times the throughput of its batch system, reducing power, magnesium, and hydrogen use. All samples met oxygen specifications, with spherical powder averaging 0.078% oxygen. The company aims for industrial-scale development.

Iperionx Limited (AU:IPX) shares rose after confirming its GenX titanium platform can operate at commercial scale, processing 500+ kg of material while meeting industry standards. The tech uses less power, boosts throughput, and reduces costs. The company controls the full titanium value chain but remains pre-revenue and cash-burning, facing future funding challenges.

IperionX received a $18.5M task order from the U.S. Army, with $11.5M funded, under an IDIQ contract for domestic titanium production. The order includes options up to $25.4M and covers equipment expansion and in-house finishing. The contract supports titanium parts for defense applications, aligning with IperionX's GenX platform.

IperionX Limited's options are under a 61-day lock-up agreement ending on 6-SEP-2026. Officers, directors, and certain securityholders agreed not to trade these options during this period. IperionX is a titanium and critical materials company with projects in the U.S. The company focuses on low-energy, low-carbon titanium production for various industries.

Jefferies initiated coverage of companies in advanced materials and energy-efficiency, citing demand from electrification, AI, and defense. Top picks include Element Solutions and Almonty Industries. The firm predicts supply bottlenecks in critical minerals, estimating $65-250 trillion in energy investment needs. Jefferies recommends focusing on companies with improving returns and margins, which have historically yielded 15% annual returns.

IperionX received $11.5M (up to $25.4M) from the U.S. Army for titanium powder and fastener production, part of a $99M SBIR Phase III program. The company aims to scale its titanium manufacturing platform and produce fasteners in-house in Virginia. IperionX also explores recycling and producing niobium powders, including the rare C103 alloy.

IperionX (IPX) secured a $19.8M U.S. Army contract for domestic titanium, with $79.2M remaining under the $99M IDIQ contract. The funding supports expanding titanium powder-to-part manufacturing capacity for defense applications, aiming to lower costs and shorten lead times. The program will increase production of titanium components like track pins and fasteners for the Army.